Regeneron board member and executive sell $1 million in stock after Trump touts treatment
“These are pre-established at a time when the executive/director is not aware of any material, nonpublic information about Regeneron,” a spokesperson said.
Related Articles
Dr. Fatima Rodriguez and Dr. C. Michael Gibson discuss: Atherosclerosis: Basic Concepts and Current Understanding – Clinical Trial Results
Sponsored by: Cleerly, Women as One and International Atherosclerosis
Zealand’s GLP-2 candidate shows early weight loss results
Zealand Pharma said that its obesity candidate that uses a unique mechanism led to notable weight loss in an early trial.
FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People
FDA Launches Agency-Wide AI Tool
How to keep weight off after obesity drugs
Nature – Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.
How to keep weight off after obesity drugs
Nature – Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.
Metsera’s amylin drug shows early potential for substantial weight loss
Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said
Metsera’s amylin drug shows early potential for substantial weight loss
Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said
Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months
In the 1980s, atherothrombosis was definitively established as the most prevalent mechanism underlying acute coronary syndromes (ACS).1,2 In the 1990s, sin
FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People
FDA Launches Agency-Wide AI Tool
Breast Cancer Patients Get Early Warning of Faltering Drugs With Blood Test
A study found that women could switch drugs without waiting for scans showing cancer progression, which improved their quality of life.